Next Investors logo grey

BPH sharpens up brain monitoring & medical marijuana efforts


Published 09-JAN-2019 10:29 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

ASX small cap, BPH Energy (ASX:BPH), has released a positive update on its progress across its diversified medtech and biotech operations.

BPH has now raised $982,504 from the rights issue announced back in October, of which $661,070 has been through shortfall applications. Together with applications received under the offset the rights issue, applications now total $1,141,040.

With this capital behind it, BPH is well-placed to implement its corporate strategy.

The company is busy progressing the commercialisation of its Cortical Dynamics Brain Anaesthesia Response (BAR Monitor or BARM). The device measures a patient’s brain electrical activity (EEG) to indicate the response to drugs administered during surgery and is the only monitor to use EEG analysis based on a model of brain electrical activity.

The BAR monitor is the core product of Cortical Dynamics, of which BPH holds a 4.47% interest, as well as a right to convert debt and increase its shareholding in the group, which could take its stake to approximately 15.7%.

In early November, Cortical CTO Louis Delacretaz attended the Korea Anaesthesia 2018 congress in Seoul.

During the congress, many anaesthetists showed strong interest in the advantages of the BARM, as compared to other monitors.

Benefits to patients include reduced risk of waking up or having recollections of surgical procedures or dreams during the surgical procedure; reduced risk of receiving too high a dose of anaesthetic agent, which can lead to post-operative nausea and discomfort, or permanent injury or death in the most severe cases; and significantly improved outcomes, particularly for patients at high risk of awareness.

Moreover, the monitor's benefits to anaesthetists include it facilitating the use of the optimal dose of anaesthetic agent and the delivery of higher quality and more reliable service to hospitals and patients. It also reduces the risk of litigation due to patients experiencing awareness during surgery.

Prior to the congress start, Delacretaz attended a series of meetings organised by Austrade with anaesthesiology professors from Korean universities.

These professors have been actively seeking a substitute for their current monitors, with strong concerns about the credibility of the current devices’ readings. They were very interested in a means to determine patients’ pain levels — and, subsequently, in trialling the BARM as a substitute device.

Cortical Dynamics’ Korean distributor, Globaluck, also introduced Delacretaz to a number of heads of leading teaching and research hospitals while in Korea.

Cortical has now engaged an international testing and certification organisation to test and certify the BARM to comply with the Korean certification process. The assessment also includes the latest medical safety standard deviations for Australia, New Zealand, European Union and the USA.

Cortical has also engaged Enable Funding to undertake a capital raising of up to $2 million at a price of 10 cents per share, and is also in discussions with other parties on further funding.

Medical cannabis

As revealed in October, BPH also plans to pursue a complementary strategy of investing in the burgeoning medical cannabis sector.

This buzzing space is showing significant growth with current developments boosting its viability. As reported by EverBlu research, legislative changes show rapid acceptance and growth.

In the last fortnight, Thailand, Israel and South Africa have all made considerable changes to laws relating to the exportation and legalisation of the drug for medical purposes.

In the US, the Food and Drug Administration (FDA) is looking for pathways to legalise the sale of CBD (cannabidiol) oil and other cannabis-based compounds in food and beverages - a move that could remove one of the last remaining legal hurdles for companies hoping to sell these kinds of products across state lines.

New Zealand has also legalised medical marijuana, and is set to hold a binding referendum on personal weed use at the 2020 general election.

In one of the most unexpected pot-related moves of 2018, South Korea's government has approved the legalisation of medical marijuana as soon as early 2019.

BPH is looking to tap a fertile market here. According to a report by Global market Insights, the global medical cannabis industry alone is projected to surpass US$55 billion (A$77.4B) by 2024.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.